Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | EVP, Research & Development | February 02, 2012 | February 06, 2012 |
| Eikon Therapeutics, Inc.EIKN · Entity 5380 | Director · See remarks | March 02, 2026 | March 04, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | Exe V-P & Pres, MRL | May 01, 2020 | May 05, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date February 02, 2012 · Filed February 06, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 261,031 |
Reported balance
After 2012-02-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2012-02-02 · Exercise / conversion · Acquired 75,000 · Balance 261,031 |
| Common StockSEC Table I · non-derivative | Direct | 186,031 |
Reported balance
After 2012-02-02 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2012-02-02 · Sale · Disposed 75,000 · Balance 186,031 F1: The price reported is an average price. The prices ranged from $69.81 to $69.89 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which fully vest on 4/29/2012; 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/28/2012; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/26/2012; and 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. |
| Nqso (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.61 · Expires 2012-03-15 | Direct | 0 |
Reported balance
After 2012-02-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2012-02-02 · Exercise / conversion · Disposed 75,000 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is an average price. The prices ranged from $69.81 to $69.89 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
F2: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which fully vest on 4/29/2012; 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/28/2012; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/26/2012; and 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
Eikon Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.88 · Expires 2036-03-01 | Direct | 268,176 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 268,176 · Balance 268,176 F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.
Merck & Co., Inc.
Report date May 01, 2020 · Filed May 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.67 · Expires 2030-04-30 | Direct | 151,029 |
Reported balance
After 2020-05-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-01 · Grant · Acquired 151,029 · Balance 151,029 F2: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. |
| Common StockSEC Table I · non-derivative | Direct | 215,059.579 |
Reported balance
Holding disclosure · report date 2020-05-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 215,059.579 F1: Holdings include shares acquired in dividend reinvestment transactions. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings include shares acquired in dividend reinvestment transactions.
F2: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NGM BIOPHARMACEUTICALS INC
Report date April 05, 2024 · Filed April 08, 2024
Section 16 reporting ended · disclosed 2024-04-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.69 · Expires 2033-05-09 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-05 · Disposition to issuer · Disposed 78,407 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.35 · Expires 2032-05-17 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-05 · Disposition to issuer · Disposed 24,222 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.24 · Expires 2031-06-07 | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-05 · Disposition to issuer · Disposed 46,238 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").
F2: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 22:00 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | GrantStock Option (Right to Buy) · Derivative | 268,176 | $0.00 Strike: $14.88 | $0.00 |
DisclosureSEC source: 0001193125-26-091779 · ownership.xml · derivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,176 Underlying: Common Stock · 268,176 shares Expires 2036-03-01 F1 · derivative.exercise_date: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:06 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries D Preferred Stock · Derivative | 855,512 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-044903 · ownership.xml · derivative · entry 3 PERLMUTTER ROGER M · CIK 0001184228 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 114,714 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F2 · price: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F2 · derivative.exercise_date: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F2 · derivative.expiration_date: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F3 · ownership.nature: The securities are held indirectly by the Reporting Person through Perlmutter Consulting, Inc. for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:06 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionSeries A-1 Preferred Stock · Derivative | 1,268,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-044903 · ownership.xml · derivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 170,143 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date. F1 · price: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date. F3 · ownership.nature: The securities are held indirectly by the Reporting Person through Perlmutter Consulting, Inc. for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:06 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | ConversionCommon Stock | 284,857 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-044903 · ownership.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 284,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date. F2 · price: The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date. F3 · ownership.nature: The securities are held indirectly by the Reporting Person through Perlmutter Consulting, Inc. for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 16:09 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerStock Option (Right to Buy) · Derivative | 46,238 | Not disclosed Strike: $17.24 | Not disclosed |
DisclosureSEC source: 0000950170-24-042588 · ownership.xml · derivative · entry 3 PERLMUTTER ROGER M · CIK 0001184228 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,238 shares Expires 2031-06-07 F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2 · derivative.exercise_price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2 · price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 16:09 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerStock Option (Right to Buy) · Derivative | 24,222 | Not disclosed Strike: $13.35 | Not disclosed |
DisclosureSEC source: 0000950170-24-042588 · ownership.xml · derivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,222 shares Expires 2032-05-17 F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2 · derivative.exercise_price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2 · price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. Read SEC document |
| April 05, 2024 Filed Apr 8, 2024 16:09 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | Disposition to issuerStock Option (Right to Buy) · Derivative | 78,407 | Not disclosed Strike: $3.69 | Not disclosed |
DisclosureSEC source: 0000950170-24-042588 · ownership.xml · derivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,407 shares Expires 2033-05-09 F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2 · derivative.exercise_price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 24, 2024 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). F2 · price: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. Read SEC document |
| May 10, 2023 Filed May 12, 2023 17:49 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | GrantStock Option (Right to Buy) · Derivative | 78,407 | $0.00 Strike: $3.69 | $0.00 |
DisclosureSEC source: 0001209191-23-029183 · doc4.xml · derivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,407 Underlying: Common Stock · 78,407 shares Expires 2033-05-09 F1 · derivative.exercise_date: The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date. Read SEC document |
| May 18, 2022 Filed May 20, 2022 18:24 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | GrantStock Option (Right to Buy) · Derivative | 24,222 | $0.00 Strike: $13.35 | $0.00 |
DisclosureSEC source: 0001209191-22-031135 · doc4.xml · derivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,222 Underlying: Common Stock · 24,222 shares Expires 2032-05-17 F1 · derivative.exercise_date: The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 17:34 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | GrantStock Option (Right to Buy) · Derivative | 46,238 | $0.00 Strike: $17.24 | $0.00 |
DisclosureSEC source: 0001209191-21-039585 · doc4.xml · derivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,238 Underlying: Common Stock · 46,238 shares Expires 2031-06-07 F1 · derivative.exercise_date: The stock option shall vest one-third on the first anniversary of the date of grant, with the remaining shares vesting quarterly over the next two years, such that the option grant will be fully vested on the third anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:52 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 151,029 | $0.00 Strike: $77.67 | $0.00 |
DisclosureSEC source: 0001127602-20-015456 · form4.xml · derivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,029 Underlying: Common Stock · 151,029 shares Expires 2030-04-30 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:39 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 35,049 | $76.56 | $2,683,351.44 |
DisclosureSEC source: 0001127602-20-009162 · form4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,428.496 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/17. Performance shares were paid out at 137 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2019. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 03, 2019 Filed May 7, 2019 23:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 141,134 | $0.00 Strike: $80.00 | $0.00 |
DisclosureSEC source: 0001104659-19-027586 · a4.xml · derivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,134 Underlying: Common Stock · 141,134 shares Expires 2029-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 32,937 | $80.38 | $2,647,476.06 |
DisclosureSEC source: 0001225208-19-003897 · doc4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,335.921 F1 · shares: Distrubtion of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/16. Performance shares were paid out at 126 percent of target awards. Includes dividends accured over the three-year performance period ending December 31, 2018. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 08, 2018 Filed Nov 8, 2018 21:31 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 225,443 | $0.00 Strike: $44.98 | $0.00 |
DisclosureSEC source: 0001225208-18-015318 · doc4.xml · derivative · entry 3 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,443 shares Expires 2023-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option became exercisable in equal installments on 5/6/2014, 5/6/2015 and 5/6/2016. Read SEC document |
| November 08, 2018 Filed Nov 8, 2018 21:31 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 225,443 | $75.27 | $16,967,967.40 |
DisclosureSEC source: 0001225208-18-015318 · doc4.xml · nonDerivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,554.968 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.2000 to $75.4500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 08, 2018 Filed Nov 8, 2018 21:31 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 225,443 | $44.98 | $10,140,426.14 |
DisclosureSEC source: 0001225208-18-015318 · doc4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,997.968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:32 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 146,383 | $0.00 Strike: $57.75 | $0.00 |
DisclosureSEC source: 0001225208-18-008939 · doc4.xml · derivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,383 Underlying: Common Stock · 146,383 shares Expires 2028-05-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| February 27, 2018 Filed Mar 2, 2018 00:32 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 34,931 | $54.72 | $1,911,424.32 |
DisclosureSEC source: 0001225208-18-005011 · doc4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,906.628 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/15. Performance shares were paid out at 138 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2017. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 05, 2017 Filed May 9, 2017 20:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 171,184 | $0.00 Strike: $63.97 | $0.00 |
DisclosureSEC source: 0001225208-17-009428 · doc4.xml · derivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,184 Underlying: Common Stock · 171,184 shares Expires 2027-05-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/5/2018, 5/5/2019 and 5/5/2020. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 32,670 | $65.85 | $2,151,319.50 |
DisclosureSEC source: 0001225208-17-005090 · doc4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,601.221 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/14. Performance shares were paid out at 158 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2016. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 10, 2016 Filed May 12, 2016 15:40 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 271,647 | $0.00 Strike: $54.68 | $0.00 |
DisclosureSEC source: 0001225208-16-033211 · doc4.xml · derivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,647 Underlying: Common Stock · 271,647 shares Expires 2026-05-09 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. Read SEC document |
| May 06, 2016 Filed May 9, 2016 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 44,464 | $54.09 | $2,405,057.76 |
DisclosureSEC source: 0001225208-16-032906 · doc4.xml · derivative · entry 3 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,464 shares Expires 2016-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 06, 2016 Filed May 9, 2016 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 26,946 | $54.09 | $1,457,509.14 |
DisclosureSEC source: 0001225208-16-032906 · doc4.xml · nonDerivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,953.392 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 06, 2016 Filed May 9, 2016 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 44,464 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-032906 · doc4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,899.392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2016 Filed Feb 24, 2016 17:38 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 25,227 | $50.77 | $1,280,774.79 |
DisclosureSEC source: 0001225208-16-027766 · doc4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,227 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance share units granted on 03/29/2013. Performance shares were paid out at 105 percent of target awards. Read SEC document |
| May 01, 2015 Filed May 5, 2015 20:46 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 247,678 | $0.00 Strike: $59.86 | $0.00 |
DisclosureSEC source: 0001225208-15-011281 · doc4.xml · derivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,678 Underlying: Common Stock · 247,678 shares Expires 2025-04-30 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 192,572 | $0.00 Strike: $58.22 | $0.00 |
DisclosureSEC source: 0001225208-14-012824 · doc4.xml · derivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,572 Underlying: Common Stock · 192,572 shares Expires 2024-05-08 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning May 9, 2015. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 225,443 | $0.00 Strike: $44.98 | $0.00 |
DisclosureSEC source: 0001225208-13-011736 · doc4.xml · derivative · entry 3 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,443 Underlying: Common Stock · 225,443 shares Expires 2023-05-05 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning May 6, 2014. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 44,464 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-011736 · doc4.xml · derivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe V-P & Pres, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,464 Underlying: Common Stock · 44,464 shares Expires 2016-05-06 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 22:35 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $58.61 | $0.00 |
DisclosureSEC source: 0001127602-12-004244 · form4.xml · derivative · entry 3 PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2012-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 22:35 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 75,000 | $69.83 | $5,237,325.00 |
DisclosureSEC source: 0001127602-12-004244 · form4.xml · nonDerivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,031 F1 · price: The price reported is an average price. The prices ranged from $69.81 to $69.89 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which fully vest on 4/29/2012; 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/28/2012; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/26/2012; and 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 22:35 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 75,000 | $58.61 | $4,395,750.00 |
DisclosureSEC source: 0001127602-12-004244 · form4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2011 Filed May 2, 2011 23:18 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,357 | $57.14 | $77,538.98 |
DisclosureSEC source: 0001127602-11-014447 · form4.xml · nonDerivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,031 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which fully vest on 4/29/2012; 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/28/2012; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/26/2012; and 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| April 28, 2011 Filed May 2, 2011 23:18 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,357 | $56.82 | $77,104.74 |
DisclosureSEC source: 0001127602-11-014447 · form4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,388 Read SEC document |
| April 26, 2011 Filed Apr 28, 2011 01:18 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,357 | $54.69 | $74,214.33 |
DisclosureSEC source: 0001127602-11-013892 · form4.xml · nonDerivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,745 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/29/2011; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/28/2011; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/26/2012; and 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| April 25, 2011 Filed Apr 28, 2011 01:18 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 55,125 | $54.69 Strike: $54.69 | $3,014,786.25 |
DisclosureSEC source: 0001127602-11-013892 · form4.xml · derivative · entry 3 PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,125 Underlying: Common Stock · 55,125 shares Expires 2021-04-25 F3 · derivative.exercise_date: These non-qualified stock options are exercisable in three annual installments of 33%, 33% and 34% on 4/25/2013, 4/25/2014 and 4/25/2015, respectively. Read SEC document |
| April 25, 2011 Filed Apr 28, 2011 01:18 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 15,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-11-013892 · form4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,102 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/25/2013, 4/25/2014 and 4/25/2015, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| March 11, 2011 Filed Mar 15, 2011 22:38 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 8,179 | $51.84 | $423,999.36 |
DisclosureSEC source: 0001127602-11-010292 · form4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,302 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/29/2011; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/28/2011; and 12,000 RSUs which vest in four equal annual installments of 3,000 each commencing 4/26/2011. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| March 02, 2011 Filed Mar 5, 2011 00:33 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 17,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-11-009093 · form4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,481 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/29/2011; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/28/2011; and 12,000 RSUs which vest in four equal annual installments of 3,000 each commencing 4/26/2011. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| April 29, 2010 Filed Apr 30, 2010 22:57 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,401 | $58.18 | $81,510.18 |
DisclosureSEC source: 0001127602-10-012677 · form4.xml · nonDerivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,961 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/29/2011; 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/28/2011; and 12,000 RSUs which vest in four equal installments of 3,000 each commencing 4/26/2011. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| April 28, 2010 Filed Apr 30, 2010 22:57 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,401 | $57.84 | $81,033.84 |
DisclosureSEC source: 0001127602-10-012677 · form4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,362 Read SEC document |
| April 26, 2010 Filed Apr 28, 2010 19:38 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 84,000 | $58.43 Strike: $58.43 | $4,908,120.00 |
DisclosureSEC source: 0001127602-10-012260 · form4.xml · derivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,000 Underlying: Common Stock · 84,000 shares Expires 2020-04-26 F3 · derivative.exercise_date: These options are exercisable in four equal annual installments of 25% each commencing 04/26/2011. Read SEC document |
| April 26, 2010 Filed Apr 28, 2010 19:38 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-10-012260 · form4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,763 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Company's 2009 Equity Incentive Plan and vest in four equal annual installments of 25% each commencing April 26, 2011. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/29/2010; 12,000 RSUs which vest in four equal annual installments of 3,000 each commencing 4/28/2010; and 12,000 RSUs which vest in four equal annual installments of 3,000 each commencing 4/26/2011. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| March 12, 2010 Filed Mar 16, 2010 19:17 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 5,753 | $57.49 | $330,739.97 |
DisclosureSEC source: 0001127602-10-008777 · form4.xml · nonDerivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,763 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's Amended and Restated 1991 Equity Incentive Plan: 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/29/2010; and 12,000 RSUs which vests in four equal annual installments of 3,000 each commencing 4/29/2010. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the reporting person. Read SEC document |
| March 12, 2010 Filed Mar 16, 2010 19:17 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 12,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-10-008777 · form4.xml · nonDerivative · entry 1 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,516 Read SEC document |
| June 02, 2009 Filed Jun 2, 2009 23:22 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 82,391 | $0.00 Strike: $38.36 | $0.00 |
DisclosureSEC source: 0001127602-09-012973 · form4.xml · derivative · entry 5 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 82,391 shares Expires 2009-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2009 Filed Jun 2, 2009 23:22 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionIso (Right to Buy) · Derivative | 2,609 | $0.00 Strike: $38.36 | $0.00 |
DisclosureSEC source: 0001127602-09-012973 · form4.xml · derivative · entry 4 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,609 shares Expires 2009-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2009 Filed Jun 2, 2009 23:22 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 85,000 | $51.07 | $4,340,865.00 |
DisclosureSEC source: 0001127602-09-012973 · form4.xml · nonDerivative · entry 3 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,192 F1 · security: These shares include the following Restricted Stock Units (RSUs) granted under the Company's Amended and Restated 1991 Equity Incentive Plan: 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/29/2010; and 12,000 RSUs which vests in four equal annual installments of 3,000 each commencing 4/29/2010. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the reporting person. F2 · price: The sale price is an average sale price with a low of $51.00 per share and a high of $51.19 per share. A detailed list of the number of shares sold and the sale price of each share is available upon request by the SEC staff, the issuer or a security holder of the issuer. Read SEC document |
| June 02, 2009 Filed Jun 2, 2009 23:22 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 82,391 | $38.36 | $3,160,518.76 |
DisclosureSEC source: 0001127602-09-012973 · form4.xml · nonDerivative · entry 2 PERLMUTTER ROGER M · CIK 0001184228 · Exe VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These shares include the following Restricted Stock Units (RSUs) granted under the Company's Amended and Restated 1991 Equity Incentive Plan: 9,000 RSUs which vest in three equal annual installments of 3,000 each commencing 4/29/2010; and 12,000 RSUs which vests in four equal annual installments of 3,000 each commencing 4/29/2010. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.